Literature DB >> 13374225

Treatment of uveitis with pyrimethamine (daraprim).

E S PERKINS, P B SCHOFIELD, C H SMITH.   

Abstract

Entities:  

Keywords:  ANTIMALARIALS/therapeutic use; UVEITIS/therapy

Mesh：

Substances：

Year:  1956        PMID： 13374225      PMCID： PMC1324697          DOI： 10.1136/bjo.40.10.577

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  10 in total

1.  Ocular toxoplasmosis; clinical and laboratory diagnosis; evaluation of immunologic tests; treatment.

Authors:  M J HOGAN
Journal:  AMA Arch Ophthalmol       Date:  1956-03

2.  Uveitis.

Authors:  R C DAVENPORT
Journal:  Proc R Soc Med       Date:  1956-01

3.  The preliminary results of the treatment of uveitis with daraprim.

Authors:  C SMITH; E S PERKINS
Journal:  Proc R Soc Med       Date:  1956-01

4.  Diagnosis and treatment of toxoplasmic uveitis.

Authors:  J J CULLIGAN; R D GUNKEL; L JACOBS; M K COOK
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1954 Nov-Dec

5.  [Treatment of experimental toxoplasmosis in white mice with plaquenil, daraprim and fumagillin].

Authors:  A TREVINO; G VARELA; L PALENCIA
Journal:  Rev Inst Salubr Enferm Trop       Date:  1953-12

6.  A study of the role of toxoplasmosis in adult chorioretinitis.

Authors:  A C WOODS; L JACOBS; R M WOOD; M K COOK
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1954 Mar-Apr

7.  Toxoplasmosis in the adult.

Authors:  S DUKE-ELDER; N ASHTON; M BRIHAYEVAN GEERTRUYDEN
Journal:  Br J Ophthalmol       Date:  1953-06       Impact factor: 4.638

8.  Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon Parasite (Toxoplasma).

Authors:  A B Sabin; H A Feldman
Journal:  Science       Date:  1948-12-10       Impact factor: 47.728

9.  Toxoplasma chorioretinitis in adults.

Authors:  H C WILDER
Journal:  AMA Arch Ophthalmol       Date:  1952-08

10.  The chemotherapeutic efficacy of 2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine (daraprim) in experimental toxoplasmosis.

Authors:  W A SUMMERS
Journal:  Am J Trop Med Hyg       Date:  1953-11       Impact factor: 2.345
  10 in total
  10 in total

1.  SPIRAMYCIN IN THE TREATMENT OF POSTERIOR UVEITIS.

Authors:  J M HEATON
Journal:  Br J Ophthalmol       Date:  1963-11       Impact factor: 4.638

2.  [Clinical study of ocular toxoplasmosis].

Authors:  R WEEKERS; M BONNET DE RUDDER; J BASSLEER
Journal:  Doc Ophthalmol       Date:  1960       Impact factor: 2.379

3.  TOXOPLASMIC uveitis and pyrimethamine.

Authors: 
Journal:  Br Med J       Date:  1957-11-02

Review 4.  Antibiotics for human toxoplasmosis: a systematic review of randomized trials.

Authors:  Senaka Rajapakse; Mitrakrishnan Chrishan Shivanthan; Nilakshi Samaranayake; Chaturaka Rodrigo; Sumadhya Deepika Fernando
Journal:  Pathog Glob Health       Date:  2013-06       Impact factor: 2.894

Review 5.  Why prevent, diagnose and treat congenital toxoplasmosis?

Authors:  Rima McLeod; Francois Kieffer; Mari Sautter; Tiffany Hosten; Herve Pelloux
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

Review 6.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

Review 7.  Management of toxoplasmosis.

Authors:  V S Georgiev
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 8.  [Ocular toxoplasmosis].

Authors:  U Pleyer; N Torun; O Liesenfeld
Journal:  Ophthalmologe       Date:  2007-07       Impact factor: 1.174

Review 9.  Antibiotics versus no treatment for toxoplasma retinochoroiditis.

Authors:  Eli Pradhan; Sanjeeb Bhandari; Ruth E Gilbert; Miles Stanford
Journal:  Cochrane Database Syst Rev       Date:  2016-05-20

Review 10.  Current treatment of toxoplasma retinochoroiditis: an evidence-based review.

Authors:  Meredith Harrell; Petros E Carvounis
Journal:  J Ophthalmol       Date:  2014-08-13       Impact factor: 1.909
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.